[go: up one dir, main page]

WO1998038985A3 - Medicament pour la prophylaxie et le traitement des maladies inflammatoires - Google Patents

Medicament pour la prophylaxie et le traitement des maladies inflammatoires Download PDF

Info

Publication number
WO1998038985A3
WO1998038985A3 PCT/EP1998/001240 EP9801240W WO9838985A3 WO 1998038985 A3 WO1998038985 A3 WO 1998038985A3 EP 9801240 W EP9801240 W EP 9801240W WO 9838985 A3 WO9838985 A3 WO 9838985A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
preventive
medicament
inflammatory diseases
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/001240
Other languages
English (en)
Other versions
WO1998038985A2 (fr
Inventor
Akira Matsumori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to AU69203/98A priority Critical patent/AU6920398A/en
Publication of WO1998038985A2 publication Critical patent/WO1998038985A2/fr
Publication of WO1998038985A3 publication Critical patent/WO1998038985A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention a pour objet un médicament pour la prophylaxie et le traitement des maladies inflammatoires. Ce médicament comprend un ingrédient actif comme substance choisie dans le groupe se composant de carvedilol, d'isomères de ce dernier, actifs sur le plan optique, de ses dérivés hydroxy-carbazole et de sels pharmacologiquement acceptables de ces derniers.
PCT/EP1998/001240 1997-03-06 1998-03-05 Medicament pour la prophylaxie et le traitement des maladies inflammatoires Ceased WO1998038985A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69203/98A AU6920398A (en) 1997-03-06 1998-03-05 Medicament for preventive and therapeutic treatment of inflammatory diseas es

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP97/51473 1997-03-06
JP9051473A JPH10251147A (ja) 1997-03-06 1997-03-06 炎症性疾患の予防・治療剤

Publications (2)

Publication Number Publication Date
WO1998038985A2 WO1998038985A2 (fr) 1998-09-11
WO1998038985A3 true WO1998038985A3 (fr) 1998-12-23

Family

ID=12887931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001240 Ceased WO1998038985A2 (fr) 1997-03-06 1998-03-05 Medicament pour la prophylaxie et le traitement des maladies inflammatoires

Country Status (3)

Country Link
JP (1) JPH10251147A (fr)
AU (1) AU6920398A (fr)
WO (1) WO1998038985A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024198A1 (fr) * 2000-09-21 2002-03-28 University Of Houston Nouvelle therapie
EP1684764A2 (fr) 2003-10-09 2006-08-02 Inverseon, Inc. Methodes de traitement de maladies et de troubles avec des agonistes inverses et de criblage d'agents agissant en tant qu'agonistes inverses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012178A1 (fr) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Utilisation cardiopretectrice antioxydante de composes d'hydroxycarbazole et procede de traitement utilisant ces composes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012178A1 (fr) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Utilisation cardiopretectrice antioxydante de composes d'hydroxycarbazole et procede de traitement utilisant ces composes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GIORA Z. FEUERSTEIN ET AL.: "Carvedilol: Preclinical profile and rationale for its use in hypertension, coronary syndromes, and congestive haert failure", CARDIOVASCULAR REVIEWS & REPORTS, vol. 17, no. 10, 1996, pages 27 - 38, XP002072749 *
GIORA.Z.FEUERSTEIN ET AL.: "Carvedilol update III: Rationale for use in congestive heart failure", DRUGS OF TODAY, vol. 31, no. suppl. F, 1995, pages 1 - 23, XP002072748 *
PETER LIU ET AL.: "Viral myocarditis: Balance between viral infection and immune response", CAN.J.CARDIOL., vol. 12, no. 10, 1996, pages 935 - 943, XP002072747 *
VINCENT R. ZALES ET AL.: "Endocarditis, pericarditis and myocarditis", PEDIATRIC ANNALS, vol. 26, no. 2, February 1997 (1997-02-01), pages 116 - 121, XP002072750 *

Also Published As

Publication number Publication date
AU6920398A (en) 1998-09-22
JPH10251147A (ja) 1998-09-22
WO1998038985A2 (fr) 1998-09-11

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
AU3990797A (en) Sustained release formulation
NO971206D0 (no) Forlenget-frigjöringsformulering
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
ITMI961152A0 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
WO2003015779A3 (fr) Systeme therapeutique transdermique a regulation matricielle permettant l'administration de pramipexol et de ropinirol
CA2382387A1 (fr) Formulations pharmaceutiques et utilisations de ces dernieres pour prevenir l'accident cerebrovasculaire, le diabete et/ou l'insuffisance cardiaque globale
WO1999004772A3 (fr) Levobupivacine et son utilisation
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
CA2253130A1 (fr) Medicament pour traiter l'obesite et ameliorer le metabolisme lipidique
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
EP1666041A3 (fr) Derivés de la xanthine contre désordres neurodégénératifs
WO2003005967A3 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
EP1440691A3 (fr) Traitement des troubles neurotiques
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
ES2109752T3 (es) Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
WO2001030331A3 (fr) Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c
CA2340734A1 (fr) Derive de pyridyl-4h-1,2,4-oxadiazine optiquement actif et son utilisation dans le traitement des maladies vasculaires
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538161

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase